a first-in-human investigation of AI-focused ultrasound for the treatment of chronic venous insufficiency and varicose veins.
Veinsound, an AI-Medtech company specializing in breakthrough AI-Focused Ultrasound (AIFU) treatments for chronic venous insufficiency (CVI) and varicose veins, today announced the successful launch of its First-in-Human (FIH) clinical trial EASY-VEIN NT. The study is conducted at leading vascular center in Europe, with the favorable opinion of the National Bioethics Committee and the authorization of the Romanian National Agency for Medicines and Medical Devices (ANMDMR). To date, the first four patients have been treated and early positive clinical observations reinforce Veinsound’s potential to bring a disruptive solution for venous diseases. “Treating the first patients marks a significant milestone in our development. This helps assess whether AIFU can treat CVI and the great saphenous vein, in an office setting, without heat, needles or catheters.
The value proposition we have championed from the start —a simple, fast, anesthesia-free and in-office treatment —is nowbecoming a clinical reality. I warmly thank the patients and the investigators who make this study possible,” says Dr. Thomas CHARREL, Chief Executive Officer of Veinsound.
